Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Protocol No
CARSGEN-CT053-MM-02
Principal Investigator
Binod Dhakal
Phase
I/II
Summary
This project is being done to see whether zevor-cel (CT053) can be used to treat others with your disease in the future.
Description
Clinical Trial to Evaluate CT053 in Patients with R/R-MM (LUMMICAR Study 2)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL